Overview

Non Small Cell Lung Cancer Therapeutics Market is poised to register a CAGR of 13.4% during the forecast period 2022 to 2028.

Any type of epithelial lung cancer that is not small-cell lung cancer is referred to as non-small-cell lung cancer. NSCLCs are less responsive to treatment than small-cell carcinomas. When possible, chemotherapy is given both preoperatively and postoperatively, although surgical excision with the goal of curing them is still the mainstay of treatment. Squamous cell carcinoma, large-cell carcinoma, and adenocarcinoma are the three most prevalent kinds of NSCLC, however a few additional types are less frequent. The less frequent varieties include pleomorphic, carcinoid tumours, salivary gland carcinoma, and unclassified carcinoma. Both unique histologic variations and mixed cell-type combinations are possible for all kinds. Nearly half of all NSCLCs are non-squamous cell carcinomas. Approximately one-ninth of the tissue classification belongs to the central type. Not else specified (NOS) is a general term used when a more precise diagnosis cannot be made. This is frequently the case when a pathologist studies a few cancer cells or tissues in a cytology or biopsy material. Never-smokers typically develop NSCLC, with adenocarcinoma making up a large component of the disease. On rare cases, SCLC and NSCLC components have been discovered in malignant lung tumours. These examples involve mixed small-cell lung carcinomas (c-SCLC), which are treated similarly to "pure" SCLC. Many of the symptoms of NSCLC can be mistaken for those of other diseases, however the presence of persistent or overlapping symptoms may be a sign that the cancer is active. While certain symptoms may indicate a less severe condition, others may indicate the disease is spreading. A chronic cough, coughing up blood, hoarseness, shortness of breath, wheezing, chest pain, weight loss, and lack of appetite are some indicators of less advanced cancer.

FutureWise Market Research has instantiated a report that provides an intricate analysis of Non Small Cell Lung Cancer Therapeutics Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.

According to the research study conducted by FutureWise research analysts, the Non Small Cell Lung Cancer Therapeutics Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

Major players included in the Non Small Cell Lung Cancer Therapeutics Market:
• Genentech (F. Hoffmann-La Roche Ltd)
• Eli Lilly and Company
• Celgene Corporation
• AstraZeneca
• Pfizer Inc.
• Sanofi
• Novartis AG
• Astellas
• Bristol Myers Squibb
• Boehringer Ingelheim Pharmaceuticals, Inc.
• Millennium Pharmaceuticals, Inc. (Takeda)
• Merck Sharp & Dohme Corp.
(Note: The list of the major players will be updated with the latest market scenario and trends)

Non Small Cell Lung Cancer Therapeutics Market Segmentation:
By Therapy
• Targeted Therapy
  o Bevacizumab
  o Dabrafenib/Trametinib
  o Erlotinib Hydrochloride
  o Osimertinib
  o Others
• Immunotherapy
  o Durvalumab
  o Nivolumab
  o Atezolizumab
  o Pembrolizumab
  o Chemotherapy

By Cancer Type  
• Adenocarcinoma
• Squamous Cell Carcinoma
• Large Cell Carcinoma

By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Others

By Region
• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa

Non Small Cell Lung Cancer Therapeutics Market Sample Video:

Competitive Landscape:
• Tier 1 players- established companies in the market with a major market share
• Tier 2 players
• Emerging players which are growing rapidly
• New Entrants

FutureWise Key Takeaways:
• Growth prospects
• SWOT analysis
• Key trends
• Key data-points affecting market growth

Objectives of the Study:
• To provide with an exhaustive analysis on the Non Small Cell Lung Cancer Therapeutics Market By Therapy, By Cancer Type, By Distribution Channel and By Region.
• To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
• To evaluate and forecast micro-markets and the overall market
• To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
• To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

Flexible Delivery Model:
• We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
• The customization Mobility Care offered are free of charge with purchase of any license of the report
• You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents

1. Market Introduction
   1.1. Objectives of the Study 
   1.2. Market Definition 
   1.3. Market Scope 
        1.3.1. Years Considered for the Study
        1.3.2. Market Covered
   1.4. Currency 
   1.5. Limitations 
   1.6. Stakeholders 

2. Research Methodology 
   2.1. Research Data 
        2.1.1. Secondary Data
               2.1.1.1. Key Data from Secondary Sources
        2.1.2. Primary Data
               2.1.2.1. Key Data from Primary Sources
   2.2. Market Size Estimation 
   2.3. Market Breakdown and Data Triangulation 
   2.4. Assumptions for the Study  

3. Executive Summary
   3.1. Market Outlook
   3.2. Segment Outlook
   3.3. Competitive Insights

4. Non Small Cell Lung Cancer Therapeutics Market Variables, Trends & Scope
   4.1. Market Lineage Outlook
   4.2. Penetration and Growth Prospect Mapping
   4.3. Industry Value Chain Analysis
   4.4. Cost Analysis Breakdown
   4.5. Technology Overview
   4.6. Regulatory Framework
        4.6.1. Reimbursement Framework
        4.6.2. Standards and Compliances

5. Market Overview
   5.1. Market Dynamics
        5.1.1. Market Driver Analysis
               5.1.1.1. Increasing focus of Non Small Cell Lung Cancer Therapeutics Market Companies on Brand Protection
               5.1.1.2. Untapped Opportunities in Emerging Regions
        5.1.2. Market Restraint Analysis
               5.1.2.1. High Cost Associated with Implementation of Predictive Analysis
        5.1.3. Industry Challenges
               5.1.3.1. Presence of Ambiguous Regulatory Framework

6. Non Small Cell Lung Cancer Therapeutics Market Analysis Tools
   6.1. Industry Analysis - Porter’s
        6.1.1. Supplier Power
        6.1.2. Buyer Power
        6.1.3. Substitution Threat
        6.1.4. Threat from New Entrants
        6.1.5. Competitive Rivalry
   6.2. Pestel Analysis
        6.2.1. Political Landscape
        6.2.2. Environmental Landscape
        6.2.3. Social Landscape
        6.2.4. Technology Landscape
        6.2.5. Legal Landscape
   6.3. Major Deals And Strategic Alliances Analysis
        6.3.1. Joint Ventures
        6.3.2. Mergers and Acquisitions
        6.3.3. Licensing and Partnership
        6.3.4. Technology Collaborations
        6.3.5. Strategic Divestments
   6.4. Market Entry Strategies
   6.5. Case Studies

7. Non Small Cell Lung Cancer Therapeutics Market, By Therapy Historical Analysis and Forecast 2022-2028 (USD Million)
   7.1. Targeted Therapy
        7.1.1. Bevacizumab
        7.1.2. Dabrafenib/Trametinib
        7.1.3. Erlotinib Hydrochloride
        7.1.4. Osimertinib
        7.1.5. Others
   7.2. Immunotherapy
        7.2.1. Durvalumab
        7.1.2. Nivolumab
        7.1.3. Atezolizumab
        7.1.4. Pembrolizumab
        7.1.5. Chemotherapy

8. Non Small Cell Lung Cancer Therapeutics Market, By Cancer Type Historical Analysis and Forecast 2022-2028 (USD Million)  
   8.1. Adenocarcinoma
   8.2. Squamous Cell Carcinoma
   8.3. Large Cell Carcinoma

9. Non Small Cell Lung Cancer Therapeutics Market, By Distribution Channel Historical Analysis and Forecast 2022-2028 (USD Million)  
   9.1. Hospital Pharmacies
   9.2. Retail Pharmacies
   9.3. Online Pharmacies
   9.4. Others

10. North America Non Small Cell Lung Cancer Therapeutics Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
    10.1. Introduction
    10.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
          10.2.1. U.S.A
          10.2.2. Canada
          10.2.3. Mexico
    10.3. Market Size (USD Million) Forecast for North America 2022-2028

11. Latin America Non Small Cell Lung Cancer Therapeutics Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
    11.1. Introduction
    11.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
          11.2.1. Brazil
          11.2.2. Venezuela
          11.2.3. Argentina
          11.2.4. Rest of Latin America
    11.3. Market Size (USD Million) Forecast for Latin America 2022-2028

12. Europe Non Small Cell Lung Cancer Therapeutics Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
    12.1. Introduction
    12.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
          12.2.1. Germany
          12.2.2. U.K         
          12.2.3. France
          12.2.4. Italy
          12.2.5. Spain
          12.2.6. Russia
          12.2.7. Poland
          12.2.8. Rest of Europe
    12.3. Market Size (USD Million) Forecast for Europe 2022-2028

13. Asia Pacific Non Small Cell Lung Cancer Therapeutics Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
    13.1. Introduction
    13.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
          13.2.1. Japan
          13.2.2. China
          13.2.3. India
          13.2.4. Australia and New Zealand
          13.2.5. ASEAN
          13.2.6. Rest of Asia Pacific
    13.3. Market Size (USD Million) Forecast for Asia Pacific 2022-2028  

14. Middle East and Africa Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
    14.1. Introduction
    14.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
          14.2.1. GCC
          14.2.2. Israel
          14.2.3. South Africa
          14.2.4. Rest of MEA
    14.3. Market Size (USD Million) Forecast for MEA 2022-2028

15. Market Share Analysis and Competitive Landscape   
    15.1. Global Landscape - Key Players, Revenue and Presence
    15.2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
    15.3. Global Emerging Companies
    15.4. North America - Market Share Analysis and Key Regional Players
    15.5. Europe - Market Share Analysis and Key Regional Players
    15.6. Asia Pacific - Market Share Analysis and Key Regional Players
    15.7. Global Key Player - Growth Matrix

16. Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
   16.1. Genentech (F. Hoffmann-La Roche Ltd)
         16.1.1. Company Overview
         16.1.2. Product Portfolio
         16.1.3. SWOT Analysis
         16.1.4. Financial Overview
         16.1.5. Strategic Overview
   16.2. Eli Lilly and Company
         16.2.1. Company Overview
         16.2.2. Product Portfolio
         16.2.3. SWOT Analysis
         16.2.4. Financial Overview
         16.2.5. Strategic Overview
   16.3. Celgene Corporation
         16.3.1. Company Overview
         16.3.2. Product Portfolio
         16.3.3. SWOT Analysis
         16.3.4. Financial Overview
         16.3.5. Strategic Overview
   16.4. AstraZeneca
         16.4.1. Company Overview
         16.4.2. Product Portfolio
         16.4.3. SWOT Analysis
         16.4.4. Financial Overview
         16.4.5. Strategic Overview
   16.5. Pfizer Inc.
         16.5.1. Company Overview
         16.5.2. Product Portfolio
         16.5.3. SWOT Analysis
         16.5.4. Financial Overview
         16.5.5. Strategic Overview          
   16.6. Sanofi
         16.6.1. Company Overview
         16.6.2. Product Portfolio
         16.6.3. SWOT Analysis
         16.6.4. Financial Overview
         16.6.5. Strategic Overview      
   16.7. Novartis AG
         16.7.1. Company Overview
         16.7.2. Product Portfolio
         16.7.3. SWOT Analysis
         16.7.4. Financial Overview
         16.7.5. Strategic Overview
   16.8. Astellas
         16.8.1. Company Overview
         16.8.2. Product Portfolio
         16.8.3. SWOT Analysis
         16.8.4. Financial Overview
         16.8.5. Strategic Overview
   16.9. Bristol Myers Squibb
         16.9.1. Company Overview
         16.9.2. Product Portfolio
         16.9.3. SWOT Analysis
         16.9.4. Financial Overview
         16.9.5. Strategic Overview
   16.10.Boehringer Ingelheim Pharmaceuticals, Inc.
         16.10.1. Company Overview
         16.10.2. Product Portfolio
         16.10.3. SWOT Analysis
         16.10.4. Financial Overview
         16.10.5. Strategic Overview
   16.11.Millennium Pharmaceuticals, Inc. (Takeda)
         16.11.1. Company Overview
         16.11.2. Product Portfolio
         16.11.3. SWOT Analysis
         16.11.4. Financial Overview
         16.11.5. Strategic Overview
   16.12.Merck Sharp & Dohme Corp.
         16.12.1. Company Overview
         16.12.2. Product Portfolio
         16.12.3. SWOT Analysis
         16.12.4. Financial Overview
         16.12.5. Strategic Overview

17. Pre and Post COVID-19 Impact
    17.1. Positive influence on the healthcare industry
    17.2. The financial disruption of the manufacturing sector
    17.3. Impact of COVID-19 on emerging companies
    17.4. Significant mandates in the regulations initiated by healthcare administrations
    17.5. The overall economic slowdown of the developing and developed nations

18. FutureWise SME Key Takeaway Points for Client

Tables

Figures